glp 1 and immune system The Cardiovascular Biology of Glucagon-like Peptide-1: Cell Metabolism Antiinflammatory actions of glucagon-like peptide-1–based

Looking for even greater savings

The August 2023 announcement of topline results was followed in November 2023 by a presentation of detailed results7, which revealed a statistically significant reduction in non-fatal myocardial infarction of 28% and smaller reductions in cardiovascular death and non-fatal stroke which were not statistically significant over the length of the trial (up to five years)

A Nature study of 27,885 people identified gene variants that predict GLP-1 weight loss and nausea risk, including one specific to Mounjaro users.

However, existing evidence remains inconclusive

Glucagon-like peptide-1 receptor agonists also lead to satiety and appetite reduction through action on the brains appetite regulation centers, leading to weight loss in obese patients

President Trump signs an executive order that aims to cut prescription drug costs in the U.S